AOD-9604 (5mg)

Description

AOD-9604 is a synthetic peptide fragment derived from human growth hormone (hGH 177–191), developed primarily for research into fat metabolism and weight management. It attracted significant attention because it was designed to reproduce some of growth hormone’s fat-mobilizing activity without its broader growth-promoting effects.

Unlike many newer research peptides, AOD-9604 has actually been investigated in human clinical trials, although its development as an anti-obesity drug was ultimately discontinued after a larger trial failed to demonstrate significant weight loss.

Product Information
AOD-9604 is a modified fragment corresponding to the 177–191 region of human growth hormone. Research has focused on its ability to influence lipolysis and fat metabolism without producing the same growth-related effects associated with full-length growth hormone.

Early clinical research produced encouraging weight-loss signals, including a 12-week trial in which 1 mg/day was associated with greater average weight loss than placebo. However, the subsequent 24-week OPTIONS study involving 536 enrolled participants tested 0.25, 0.5, and 1 mg/day and failed to demonstrate a statistically significant weight-loss advantage over placebo.

How Does AOD-9604 Work?
AOD-9604 was designed to stimulate fat-mobilization pathways, particularly lipolysis, while avoiding many of the growth-promoting actions of full-length growth hormone.

AOD-9604 Benefits
Supports Fat-Metabolism Research
AOD-9604 has been extensively investigated for its ability to promote lipolysis and influence fat metabolism. Animal studies showed reductions in body weight and fat accumulation, which helped drive its development as an experimental obesity compound.

Research Into Body-Fat Reduction
Early human trials produced a measurable weight-loss signal, with approximately 2.6 kg of average weight loss reported after 12 weeks at 1 mg/day compared with approximately 0.8 kg with placebo. These findings generated considerable interest in AOD-9604 as a targeted fat-metabolism peptide.

Designed to Avoid Growth-Hormone Effects
A major attraction of AOD-9604 is its design. Researchers sought to retain the lipolytic portion of growth hormone activity without stimulating growth-related pathways, making it fundamentally different from administering full-length HGH.

Continued Interest in Metabolic Research
Although the larger obesity trial was unsuccessful, AOD-9604 remains of interest in research surrounding adipose tissue, lipid metabolism, and body composition. Its development history also provides a useful example of why promising early peptide data do not always translate into successful large-scale clinical outcomes.